WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Ionis’ WAINUA™ (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in ...
"Alterations in axonal membrane and channel function occur early in the disease course, prior to discernable large fibre involvement, and has the potential to be used as an early biomarker of ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...
Polyneuropathy occurs when multiple peripheral nerves malfunction throughout the body. Neuropathy is a common complication of type 2 diabetes mellitus (T2DM). Polyneuropathy occurs when there is ...
(MENAFN- GetNews) The Chronic Inflammatory Demyelinating Polyneuropathy market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results